0001437749-23-013984.txt : 20230511 0001437749-23-013984.hdr.sgml : 20230511 20230511170408 ACCESSION NUMBER: 0001437749-23-013984 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230511 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diffusion Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001053691 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300645032 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37942 FILM NUMBER: 23912072 BUSINESS ADDRESS: STREET 1: 300 EAST MAIN STREET STREET 2: SUITE 201 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: (434) 220-0718 MAIL ADDRESS: STREET 1: 300 EAST MAIN STREET STREET 2: SUITE 201 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 FORMER COMPANY: FORMER CONFORMED NAME: RestorGenex Corp DATE OF NAME CHANGE: 20140307 FORMER COMPANY: FORMER CONFORMED NAME: Stratus Media Group, Inc DATE OF NAME CHANGE: 20080722 FORMER COMPANY: FORMER CONFORMED NAME: FERIS INTERNATIONAL, INC. DATE OF NAME CHANGE: 20080228 8-K 1 dffn20230511_8k.htm FORM 8-K dffn20230511_8k.htm
false 0001053691 0001053691 2023-05-11 2023-05-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): May 11, 2023
 
 
DIFFUSION PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
 
Delaware
000-24477
30-0645032
(State or other jurisdiction of incorporation)
(Commission File
Number)
(I.R.S. Employer
Identification No.)
 
300 East Main Street, Suite 201
Charlottesville, Virginia
22902
(Address of principal executive offices)
(Zip Code)
 
(434) 220-0718
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☒
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
DFFN
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company         ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐
 
 
 
 
Item 8.01          Other Events
 
As previously announced, on March 30, 2023, Diffusion Pharmaceuticals Inc., a Delaware corporation (“Diffusion”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Diffusion, EIP Pharma, Inc., a Delaware corporation (“EIP”), and Dawn Merger Sub Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Diffusion (“Merger Sub”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will be merged with and into EIP (the “Merger”) at the effective time of the Merger, with EIP continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Diffusion.
 
On May 11, 2023, EIP issued a press release announcing that EIP’s senior management team will present at the JMP Securities Life Sciences Conference (the “Conference”) on Monday, May 15, 2023 at 11:00 a.m. ET and that EIP will also be holding one-on-one meetings at the Conference. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01 – Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit
Number
Description
   
99.1
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: May 11, 2023
DIFFUSION PHARMACEUTICALS INC.
  
       
       
 
By:
/s/ William Elder
  
 
Name:
William Elder
  
 
Title:
General Counsel & Corporate Secretary
  
 
 
 
 
 EX-99.1 2 ex_519376.htm EXHIBIT 99.1 ex_519376.htm
 

Exhibit 99.1

 

eip.jpg
 

EIP Pharma to Present at JMP Securities Life Sciences Conference

 

 

BOSTON, MA – May 11, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET. The company will also be holding 1x1 meetings at the conference.

 

A live webcast of the presentation, along with accompanying slides, can be accessed here, and will be available for replay for 90 days following the event.

 

About EIP Pharma

 

EIP Pharma, Inc. is a privately held clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. EIP Pharma is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Current institutional investors in EIP Pharma include Access Industries, Adage Capital Management, Mossrock Capital and Rock Springs Capital.

 

For more information, please visit www.eippharma.com or engage with us on Twitter and LinkedIn.

 

Forward-Looking Statements

 

This press relates includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, but not limited to, the potential of neflamapimod to treat the underlying DLB disease process and to be the first disease-modifying treatment for DLB. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “suggest” “potential” or other words that convey uncertainty of future events or outcomes may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement.

 

Contacts

 

Investors & Media:

Argot Partners

212.600.1902

EIP@argotpartners.com

 

1
 

 

eip.jpg

 

No Offer or Solicitation

 

This press release does not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

 

Important Additional Information and Where to Find It

 

In connection with a proposed transaction between Diffusion Pharmaceuticals, Inc. (Diffusion Pharmaceuticals) and EIP Pharma, Diffusion Pharmaceuticals has filed with the Securities and Exchange Commission (SEC) a registration statement containing a proxy statement and prospectus related to a special meeting of its stockholders. Diffusion Pharmaceuticals will mail the definitive proxy statement and prospectus to Diffusion Pharmaceuticals’ stockholders as of the record date to be established for voting on the merger and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THESE MATERIALS – INCLUDING THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ANY DOCUMENTS INCORPORATED THEREIN – CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DIFFUSION PHARMACEUTICALS, EIP PHARMA, THE PROPOSED TRANSACTION AND RELATED MATTERS. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Diffusion Pharmaceuticals may file with the SEC or send to Diffusion Pharmaceuticals’ stockholders in connection with the proposed transaction. Investors and stockholders may obtain free copies of the proxy statement, prospectus and other documents filed by Diffusion Pharmaceuticals with the SEC (as they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and stockholders may obtain free copies of the proxy statement, prospectus and other documents filed by Diffusion Pharmaceuticals with the SEC by contacting Diffusion Pharmaceuticals by mail at 300 East Main Street, Suite 201, Charlottesville, VA 22902, Attn: Corporate Secretary.

 

Participants in the Solicitation

 

Diffusion Pharmaceuticals and EIP Pharma, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding these persons and their interests in the transaction is or will be included in the prospectus and proxy statement relating to the transaction and other relevant materials to be filed with the SEC. Additional information regarding Diffusion Pharmaceuticals’ directors and officers is included in Diffusion Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 24, 2023. These documents can be obtained free of charge from the SEC and Diffusion Pharmaceuticals sources indicated above.

 

 

2
 EX-101.SCH 3 dffn-20230511.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 dffn-20230511_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 dffn-20230511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 dffn-20230511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 eip.jpg begin 644 eip.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
May 11, 2023
Document Information [Line Items]  
Entity, Registrant Name DIFFUSION PHARMACEUTICALS INC.
Document, Type 8-K
Document, Period End Date May 11, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 000-24477
Entity, Tax Identification Number 30-0645032
Entity, Address, Address Line One 300 East Main Street, Suite 201
Entity, Address, City or Town Charlottesville
Entity, Address, State or Province VA
Entity, Address, Postal Zip Code 22902
City Area Code 434
Local Phone Number 220-0718
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol DFFN
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001053691

XML 9 dffn20230511_8k_htm.xml IDEA: XBRL DOCUMENT 0001053691 2023-05-11 2023-05-11 false 0001053691 8-K 2023-05-11 DIFFUSION PHARMACEUTICALS INC. DE 000-24477 30-0645032 300 East Main Street, Suite 201 Charlottesville VA 22902 434 220-0718 true false false false Common Stock DFFN NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.dffn.com/20230511/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports dffn20230511_8k.htm dffn-20230511.xsd dffn-20230511_def.xml dffn-20230511_lab.xml dffn-20230511_pre.xml ex_519376.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dffn20230511_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "dffn-20230511_def.xml" ] }, "inline": { "local": [ "dffn20230511_8k.htm" ] }, "labelLink": { "local": [ "dffn-20230511_lab.xml" ] }, "presentationLink": { "local": [ "dffn-20230511_pre.xml" ] }, "schema": { "local": [ "dffn-20230511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dffn", "nsuri": "http://www.dffn.com/20230511", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dffn20230511_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.dffn.com/20230511/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dffn20230511_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.dffn.com/20230511/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001437749-23-013984-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-013984-xbrl.zip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